Answers are grounded in this paper and cite their sources.
Multi-institutional analysis explores aspirin's impact on liver-related events and mortality in MASLD, suggesting potential benefits.
Background The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is increasing. While daily aspirin use has been associated with reduced hepatocellular carcinoma (HCC) risk in NAFLD, its impact on mortality and liver-related outcomes in MASLD remains unclear.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: